This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Hirono, K. Articles by Miyawaki, T. Search for Related Content PubMed PubMed Citation Articles by Hirono, K. Articles by Miyawaki, T. Related Collections Related Article

Expression of Myeloid-Related Protein-8 and -14 in Patients With Acute Kawasaki Disease

Keiich Hirono, MD^_*, Dirk Foell, MD, Yanlin Xing, MD^_*, Sachiko Miyagawa-Tomita, PhD, Fei Ye, MD^_*, Martina Ahlmann, MD, Thomas Vogl, PhD, Takeshi Futatani, MD^_*, Chen Rui, MD^_*, Xianyi Yu, MD^_*, Kazuhiro Watanabe, MD^_*, Sayaka Wanatabe, MD^_*, Shinichi Tsubata, MD^_*, Keiichiro Uese, MD^_*, Ikuo Hashimoto, MD^_*, Fukiko Ichida, MD^_*,_*, Makoto Nakazawa, MD, Johannes Roth, MD and Toshio Miyawaki, MD^_*

^_* Department of Pediatrics, Toyama University, Toyama, Japan
Department of Pediatrics, Muenster University, Muenster, Germany
Department of Pediatric Cardiology, Tokyo Women’s Medical University, Tokyo, Japan
Institute of Experimental Dermatology, Muenster University, Muenster, Germany.

View larger version (12K): [in a new window]   Figure 1 Serum levels of myeloid-related protein (MRP)-8/MRP-14 in patients with acute Kawasaki disease comparing patients who responded to intravenous immune globulin (IVIG) treatment (left panel) with those who did not (right panel). Blood samples were collected at the time of diagnosis before the initiation of IVIG treatment (5.7 ± 1.5 days). Arrows indicate IVIG treatment. *p < 0.01 versus healthy control patients. p < 0.01 versus before IVIG in each patient group.

View larger version (13K): [in a new window]   Figure 2 Expressions of myeloid-related protein (MRP)-8 (left panel) and -14 (right panel) in granulocytes in acute Kawasaki disease patients who responded to intravenous immune globulin (IVIG) (closed circles) and those who did not (open circles). *p < 0.05 versus healthy control patients. p < 0.05 versus before IVIG treatment in responders.

View larger version (29K): [in a new window]   Figure 3 Immunocytochemical analysis of circulating cells. (A) Buffy-coat smear-stained with P1H12 showing a circulating endothelial cell (red staining) (magnification x1,000) (left). A circulating endothelial cell stained for myeloid-related protein (MRP)-8/MRP-14 (green staining) (magnification x1,000) (center) in acute Kawasaki disease (KD) patients with coronary artery lesions (CAL). Nuclei stained with DAPI (magnification x1,000 (right). (B) Quantitation of circulating endothelial cells (left) and cells positive for MRP-8/MRP-14 (right) in patients with acute KD with or without CAL. *p < 0.05 patients without CAL versus patients with CAL. Black columns = patients with CAL (n = 9); white columns = patients without CAL (n = 15).

View larger version (11K): [in a new window]   Figure 4 (A) Myeloid-related protein (MRP)-8/MRP-14 levels in the supernatant after stimulation of granulocytes with tumor necrosis factor (TNF)-alpha (left) or mononuclear cells with phorbol 12-myristate 13-acetate (right). (B) Relative quantification of MRP-8 (left) and MRP-14 (right) mRNA in granulocytes after stimulation with TNF-alpha. *p < 0.01 versus before stimulation. p < 0.05 versus before stimulation.